Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabotegravir Formulations F and G in Healthy Adults
NCT06033547Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Sep 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cabotegravir in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Primary endpoints: Maximum observed plasma concentration of cabotegravir at 52 weeks, Time of maximum observed plasma concentration of cabotegravir at 52 weeks and 7 more. Started Sep 2023; status: completed.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06033547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06033547.